186497-89-2

Basic information

• Product Name: Methyl 4-(3-{[(3-Methoxy-5-Methylpyrazin-2-yl)[(2-Methylpropoxy)carbonyl]aMino]sulfonyl}pyridin-2-yl)benzoate
• Synonyms: Methyl 4-(3-{[(3-Methoxy-5-Methylpyrazin-2-yl)[(2-Methylpropoxy)carbonyl]aMino]sulfonyl}pyridin-2-yl)benzoate;Methyl 4-(3-(N-(isobutoxycarbonyl)-N-(3-Methoxy-5-Methylpyrazin-2-yl)sulfaMoyl)pyridin-2-yl)benzoate
• CAS NO: 186497-89-2
• Molecular Formula: C24H26N4O7S
• Molecular Weight: 514.55084
• Mol File: 186497-89-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 4-(3-{[(3-Methoxy-5-Methylpyrazin-2-yl)[(2-Methylpropoxy)carbonyl]aMino]sulfonyl}pyridin-2-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(3-{[(3-Methoxy-5-Methylpyrazin-2-yl)[(2-Methylpropoxy)carbonyl]aMino]sulfonyl}pyridin-2-yl)benzoate(186497-89-2)
• EPA Substance Registry System: Methyl 4-(3-{[(3-Methoxy-5-Methylpyrazin-2-yl)[(2-Methylpropoxy)carbonyl]aMino]sulfonyl}pyridin-2-yl)benzoate(186497-89-2)

Safety Data

• Hazardous Substances Data: 186497-89-2(Hazardous Substances Data)

Usage

InChI:InChI=1S/C24H26N4O7S/c1-15(2)14-35-24(30)28(21-22(33-4)27-16(3)13-26-21)36(31,32)19-7-6-12-25-20(19)17-8-10-18(11-9-17)23(29)34-5/h6-13,15H,14H2,1-5H3

Upstream product

• 186497-45-0 2-chloro-N-isobutoxycarbonyl-N-(3-methoxy-5-methylpyrazin-2-yl)-pyridine-3-sulphonamide 
• 99768-12-4 4-methoxycarbonylphenylboronic acid 

Relevant articles and documents

Heterocyclic compounds

The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.